Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Graves’ Ophthalmopathy - Overview
Graves’ Ophthalmopathy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Graves’ Ophthalmopathy - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Graves’ Ophthalmopathy - Companies Involved in Therapeutics Development
advanceCor GmbH
Chugai Pharmaceutical Co Ltd
Enceladus Pharmaceuticals BV
Genmab AS
GlaxoSmithKline Plc
Hall Biopharma Co Ltd
Graves’ Ophthalmopathy - Drug Profiles
batoclimab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
belimumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
prednisolone sodium phosphate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides for Graves Diseases and Graves Ophthalmopathy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
teprotumumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tocilizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Graves’ Ophthalmopathy - Dormant Projects
Graves’ Ophthalmopathy - Product Development Milestones
Featured News & Press Releases
Jun 01, 2020: Harbour BioMed receives Chinese regulatory approval of IND application to begin Seamless Phase 2/3 clinical trial of HBM9161 in Graves’ ophthalmopathy
May 14, 2020: New data on the pharmacokinetic profile of TEPEZZA (teprotumumab-trbw) reinforce the labeled dosing regimen, indicating a positive, consistent response to therapy
Mar 31, 2020: TEPEZZA (teprotumumab-trbw) significantly reduces proptosis (Eye Bulging), a key marker of thyroid eye disease, across patient subtypes
Mar 30, 2020: Immunovant announces positive clinical results from ongoing phase 2a proof-of-concept study of IMVT-1401, A novel investigatiol Anti-FcRn Antibody delivered by Subcutaneous Injection, in Thyroid Eye Disease
Feb 09, 2020: New treatment discovered for rare eye disease may prevent blindness
Jan 22, 2020: The New England Jourl of Medicine publishes comprehensive data from phase 3 clinical trial (OPTIC) of TEPEZZA (teprotumumab-trbw) for thyroid eye disease
Jan 22, 2020: Horizon Therapeutics gets FDA approval for thyroid eye disease drug
Dec 13, 2019: FDA Advisory Committee votes unimously to support the use of Teprotumumab for the treatment of Thyroid Eye Disease (TED)
Nov 25, 2019: Immunovant initiates dosing in ASCEND-GO 2, a Phase 2b Trial of IMVT-1401 in patients with Graves’ Ophthalmopathy (GO)
Nov 04, 2019: Clinical study data highlighting the impact of teprotumumab in patients with active thyroid eye disease to be presented During ACR Annual Meeting
Oct 24, 2019: New combined data from the phase 2 and phase 3 teprotumumab clinical trials to be presented during the American Thyroid Association Annual Meeting
Oct 11, 2019: New data from Teprotumumab phase 3 OPTIC study shows significantly reduced double vision and improved quality of life for people with active thyroid eye disease
Oct 08, 2019: New data insights from the phase 3 teprotumumab trial (OPTIC) to be presented at the American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS) Scientific Symposium
Sep 09, 2019: Horizon Therapeutics announces the FDA has granted priority review of the Teprotumumab Biologics License Application (BLA) for the treatment of active thyroid eye disease (TED)
Aug 19, 2019: American Jourl of Ophthalmology (AJO) publishes review highlighting lack of treatments for active thyroid eye disease (TED)
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Graves’ Ophthalmopathy, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020


List of Tables


Number of Products under Development for Graves’ Ophthalmopathy, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Graves’ Ophthalmopathy - Pipeline by advanceCor GmbH, H1 2020
Graves’ Ophthalmopathy - Pipeline by Chugai Pharmaceutical Co Ltd, H1 2020
Graves’ Ophthalmopathy - Pipeline by Enceladus Pharmaceuticals BV, H1 2020
Graves’ Ophthalmopathy - Pipeline by Genmab AS, H1 2020
Graves’ Ophthalmopathy - Pipeline by GlaxoSmithKline Plc, H1 2020
Graves’ Ophthalmopathy - Pipeline by HanAll Biopharma Co Ltd, H1 2020
Graves’ Ophthalmopathy - Dormant Projects, H1 2020